BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Will FDA Grant Accelerated Approval to Johnson & Johnson (JNJ) TB Drug?


12/28/2012 6:56:25 AM

As a deadline looms today for the FDA to grant accelerated approval to a new, first-in-class medication for treating tuberculosis, a watchdog group is urging the agency not do so, because clinical trials demonstrated an “alarming increased risk of death.” The drug, which is called Sirturo, or bedaquiline, was developed by Johnson & Johnson. In a recent letter to the FDA, Public Citizen says the FDA should not confer accelerated approval – which is granted to meds to treat serious diseases and fill an unmet medical need based on a surrogate endpoint – because patents taking the drug in addition to standard TB treatment during a Phase II trial were five times likelier to die than those who took a placebo. “It is not possible to conclude that a surrogate endpoint is “reasonably likely” to predict benefit for patients — as required by FDA regulations — when the same clinical trial of a drug using that surrogate endpoint shows a significant increase in mortality, regardless of the drug’s effects on the surrogate marker,” the watchdog writes to the FDA. “The only reasonable conclusion in such cases is that the selected surrogate endpoint is, in fact, not a valid or useful marker of clinical benefit; its surrogate ‘benefit’ is trumped by increases in the adverse clinical outcome — death — nullifying the use of the favorable surrogate marker as a means of granting accelerated approval.” Public Citizen, in fact, goes on to say that the NDA, or New Drug Application, for bedaquiline should never have been brought before an FDA advisory committee for consideration. Late last month, however, the Anti-Infective Drugs Advisory Committee voted unanimously to recommend that the FDA grant accelerated approval status.

Read at Pharmalot

Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES